| |
Title
|
|
1/1a)
|
Identify the report as a systematic review, meta-analysis, or both for pediatric population as a focus of review, if applicable
|
62.1 (248)
|
72.4 (76)
|
0.102
|
| |
Introduction
|
| |
Rationale
|
|
5/6)
|
Describe the rationale for the review in the context of what is already known
|
| |
In the contexts of the synthesized evidence in adults or other pediatric groups (non-targeted), explain the rationale for synthesizing evidence for the targeted pediatric age group(s). Provide hypotheses that relate to the targeted pediatric age group(s)
|
3.6 (248)
|
1.3 (76)
|
0.309
|
| |
Objectives
|
|
4/7)
|
Provide an explicit statement of questions being addressed with reference to targeted pediatric age groups, interventions, comparisons, outcomes, and study design (PICOS)
|
0.8 (248)
|
0 (76)
|
0.433
|
| |
Methods
|
| |
Eligibility criteria
|
|
6/8)
|
Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale
|
|
6a/8a)
|
Justify the targeted pediatric age group(s) selected
|
74.2 (248)
|
64.5 (76)
|
0.1
|
|
6b/8b)
|
Intervention: Justify the intervention for the targeted pediatric age group(s) addressing potential age-related differences in intervention effects
|
67.7 (248)
|
55.3 (76)
|
0.047*
|
|
6c/8c)
|
Provide rationale for extrapolation or adaptation of adult intervention, if any
|
29.6 (27)
|
16.7 (18)
|
0.331
|
|
6d/8d)
|
Comparators: Explain the choice of comparator(s) and, if applicable, evidence for the active comparator and/or standard of care for targeted pediatric age group(s)
|
9.7 (248)
|
17.1 (76)
|
0.076
|
|
6e/8e)
|
Outcomes: List and define all the primary outcomes addressed for the targeted pediatric age group(s). List and define growth and development outcomes, adverse outcomes (events), if applicable
|
41.1 (248)
|
55.3 (76)
|
0.031*
|
|
6f/8f)
|
Outcomes: Explain the clinical relevance of the selected outcomes (benefits and harms) for the targeted pediatric age group(s)
|
34.3 (248)
|
28.9 (76)
|
0.388
|
|
6g/8g)
|
Outcomes: Explain the validity, feasibility and responsiveness of the outcome measures for the pre-targeted pediatric age group(s)
|
0 (248)
|
0 (76)
|
p > 0.999
|
| |
Search
|
|
8/10)
|
Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated
| | | |
|
8a/10a)
|
Describe the search strategy and terms (including database specific MeSH terms for pediatric population) used to address the targeted pediatric age group(s)
|
44 (248)
|
48.7 (76)
|
0.469
|
| |
Synthesis of results
|
|
14/15b)
|
Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis
| | | |
|
14a/15b)
|
For studies that included pediatrics and adults without a subgroup analysis of the pediatric population, describe how the data on targeted pediatric age group(s) were used in the analysis
|
0 (89)
|
0 (27)
|
p > 0.999
|
| |
Additional analyses
|
|
16/15c)
|
Describe methods of additional analyses (e.g., sensitivity or subgroup analyses for targeted pediatric age group(s), meta-regression), if done, indicating which were pre-specified
|
54.9 (142)
|
61 (59)
|
0.429
|
| |
Funding
|
|
27/5)
|
Describe sources of funding for the systematic review and other support (e.g., supply of data) and role of funders for the systematic review
|
|
27a/5a)
|
For each included trial in a systematic review, indicate (a plan to include) the source of financial support (such as Government, Academia or Industry), if any, in the trial(s)
|
5.6 (248)
|
13.2 (76)
|
0.03*
|
